Hypoxia Induces Late Preconditioning in the Rat Heart
In Vivo


ABSTRACT

Background: Although hypoxic late preconditioning (LPC) limits ischemia-reperfusion injury in vitro, its cardioprotective effect is not established in vivo.

Methods: In part 1, rats were exposed to 4 h of hypoxia (16%, 12%, 8% oxygen) before 24 h of reoxygenation. In part 2, normoxic rats received early preconditioning with sevoflurane (1 minimum alveolar concentration [MAC] for 3 × 5 min), continuous administration of 1 MAC sevoflurane, or 11 mg·kg⁻¹·h⁻¹ propofol. Thereafter, all rats underwent 25 min of regional myocardial ischemia and 120 min of reperfusion. After reperfusion, hearts were excised for infarct staining. The expression of protein kinase C (PKC)α and PKCe was assessed by Western blot analysis and the expression of heme oxygenase-1 and vascular endothelial growth factor by reverse transcriptase polymerase chain reaction.

Results: In normoxic control rats, infarct size was 62 ± 6% of the area at risk. Hypoxic LPC reduced infarct size (LPC16: 36 ± 11%, LPC12: 38 ± 10%, LPC8: 39 ± 11%; each P < 0.001) to approximately the same magnitude as sevoflurane preconditioning (40 ± 8%; P < 0.001). Combined LPC16 and sevoflurane preconditioning was not superior to either substance alone. Continuous sevoflurane or propofol was not protective. The PKC inhibitor calphostin C abolished the cardioprotective effects of LPC16. PKCe, but not PKCα, expression was increased 6 and 28 h after hypoxic LPC. Heme oxygenase-1 and vascular endothelial growth factor were transiently up-regulated after 6 h.

Conclusion: Hypoxic LPC at 8%, 12%, and 16% oxygen reduces infarct size in the rat heart in vivo. This effect is as powerful as sevoflurane-preconditioning. PKCe is a key player in mediating hypoxic LPC.

What We Already Know about This Topic

❖ Hypoxic late preconditioning (LPC) is a cardioprotective strategy that increases resistance to ischemia and reperfusion by eliciting innate protective mechanisms.

What This Article Tells Us That Is New

❖ The signaling enzyme, PKCe, is essential mediating hypoxia-induced LPC in the rat heart in vivo.
❖ Hypoxia-induced LPC is as potent as sevoflurane-induced preconditioning in reducing infarct size.

I SCHEMATIC heart disease and heart failure are among the leading causes of morbidity and mortality in the Western world1,2 and of significant relevance to perioperative medicine. Perioperative myocardial infarction occurs in approximately 4% of patients with either an established diagnosis or risk for coronary artery disease undergoing major noncardiac

* Staff Anesthesiologist, Department of Anesthesiology, University Hospital of Heidelberg, Heidelberg, Germany. † Resident, ‡ Research Scientist, Department of Anesthesiology, § Doctoral Student, § Associate Professor, ††Professor and Chair, Department of Anesthesiology, " Assistant Professor, †‡ Professor and Chair, Department of Experimental and Clinical Experimental Anesthesiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Received from the Department of Anesthesiology, University Hospital of Heidelberg, Heidelberg, Germany; Departments of Anesthesiology and Hemostasis and Transfusion Medicine, University Hospital of Duesseldorf, Duesseldorf, Germany; Departments of Anesthesiology, Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Submitted for publication April 5, 2010. Accepted for publication September 13, 2010. Supported by the European Association of Cardiothoracic Anaesthesiologists (Dublin, Ireland) (to Dr. Huhn). Drs. Berger and Huhn contributed equally to this work. Presented in part at the Annual Meeting of the European Society of Anaesthesiology, Euroanaesthesia, Milan, Italy, June 7, 2009, and at the Annual Meeting of the American Society of Anaesthesiologists, New Orleans, Louisiana, October 18, 2009.

Address correspondence to Dr. Huhn: Department of Anesthesiology, University Hospital Duesseldorf, Moorstrasse 5, 40225, Dueseldorf, Germany. Ragnar.Huhn@uni-duesseldorf.de. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. ANESTHESIOLOGY’s articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.

Anesthesiology, V 113 • No 6 • December 2010 1351
In patients undergoing elective vascular surgery, myocardial infarction is the most common fatal complication, accounting for approximately 40% of postoperative fatalities within the first 4 yr. These data suggest that, particularly in high-risk patients, the choice of an anesthetic regimen that preserves myocardial function may improve postoperative outcome.

Myocardial damage results from an insufficiency of oxygen supply to cardiac cells to meet metabolic demands. It is well established that survival of myocardial tissue subjected to ischemia can be increased by previous exposure to repeated brief episodes of sublethal ischemia induced by transient coronary artery occlusion and reperfusion, a phenomenon known as ischemic preconditioning. Two phases of preconditioning are delineated, an early phase (EPC), which develops more slowly (requiring 6–12 h) but lasts for 2–3 h, and a late phase known as ischemic preconditioning.6 Two phases of preconditioning with sevoflurane reduced the incidence of cardiac events during the first year after coronary artery bypass surgery to 3% from 17%.

Several in vitro studies indicate that hypoxic LPC might be another powerful tool to protect against myocardial ischemia–reperfusion injury.11–15 However, there are no in vivo studies investigating the effect and concentration dependence of hypoxia-induced LPC on the magnitude of myocardial ischemia–reperfusion injury. Therefore, the goal of the current study was to investigate whether different concentrations of sustained hypoxia induce LPC in the rat heart in vivo. We also sought to determine the potency of this effect as compared with the well-established effect of EPC with sevoflurane. In addition, we tested whether the combination of hypoxic LPC with sevoflurane EPC is more effective than each stimulus alone. The signaling pathway involved in hypoxic LPC was investigated with special emphasis on the protein kinase C (PKC) isoforms PKCα and PKCe and on the expression of the hypoxia-inducible factor-1α-dependent genes heme oxygenase-1 (HO-1) and vascular endothelial growth factor (VEGF), which have previously been implicated in the genesis of hypoxic and ischemic preconditioning.14–18

Hypoxic gas mixtures were purchased from Linde Gas (Linde Gas Benelux BV, Dieren, The Netherlands). PKCα antibody was purchased from Millipore Corporation (Billerica, MA) and the PKCα antibody from Upstate Biotechnology, Inc. (Lake Placid, NY). All other chemicals were purchased from Sigma-Aldrich Chemie BV (Zwijndrecht, The Netherlands). Male Wistar rats (323 ± 23 g) were obtained from Harlan (The Hague, The Netherlands) and kept with free access to standard food and water.

Hypoxic Exposure

Rats were placed in a plexiglass chamber and randomly exposed to different concentrations of normobaric hypoxia (16%, 12%, and 8% oxygen, respectively) for 4 h by using prepared gas mixtures with the corresponding oxygen concentrations balanced with nitrogen. Normoxic control experiments were conducted identically, except that room air (21% oxygen) instead of nitrogen was introduced into the chamber. Fresh gas flow was kept at 3 l/min to ensure that no accumulation of carbon dioxide occurred, which in turn might have affected ventilation and thus oxygenation. Oxygen concentration within the chamber was controlled continuously (Capnomac Ultima;Datex-Ohmeda, Helsinki, Finland). After 4 h of hypoxic exposure, all rats were exposed to room air for 24 h.

Experimental Protocol for Determining Infarct Size

Surgical preparation was performed as described previously.19,20 In brief, rats were anesthetized by intraperitoneal S-ketamine injection (150 mg/kg) followed by continuous 30 mg · kg⁻¹ · h⁻¹ α-chloralose infusion, except for the groups that received sevoflurane (1 minimum alveolar concentration [MAC] or continuous 11 mg · kg⁻¹ · h⁻¹ propofol). After tracheal intubation, the lungs were ventilated with 30% oxygen and 70% nitrogen and a positive end-expiratory pressure of 2–3 cm H₂O. The right jugular vein was cannulated for saline and drug infusion; the left carotid artery was cannulated for measurement of aortic pressure. A lateral left-sided thoracotomy followed by pericardiotomy was performed, and a ligature (5-0 Prolene) was passed below a major branch of the left coronary artery for a later occlusion of 25 min during the experiments. Aortic pressure and electrocardiographic signals were digitized using an analog-to-digital converter (PowerLab/8SP; ADInstruments Pty, Ltd., Castle Hill, Australia) and were continuously recorded on a personal computer (version 5; Chart for Windows; ADInstruments Pty, Ltd.).

After 120 min of reperfusion, the heart was excised and mounted on a modified Langendorff apparatus for infarct staining.21 After staining with 0.2% Evans blue, the heart was cut into transverse slices, which were then stained with 0.75% triphenyltetrazolium chloride solution. The area of risk and the infarcted area were determined by planimetry (SigmaScan Pro 5.0®; SPSS Science Software, Chicago, IL).

Materials and Methods

The current investigation was conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (Publication number 85–23, revised 1996) and was performed after obtaining approval from the Animal Ethics Committee of the University of Amsterdam, The Netherlands.
Study Design

The experimental protocol is shown in figure 1.

Part 1 (n = 7–8): Effect of Hypoxic LPC at Different Oxygen Concentrations. Rats were treated according to the following protocol (fig. 1A): 24 h before the ischemia–reperfusion sequence started, LPC rats were exposed for 4 h to 21% oxygen (normoxic control), 16% oxygen (LPC16), 12% oxygen (LPC12), or 8% oxygen (LPC8), respectively. To investigate further whether the effect of hypoxic LPC can be blocked by a specific PKC inhibitor, normoxic control rats and LPC16 rats received calphostin C (0.1 mg/kg) intravenously 35 min before myocardial ischemia was induced.

Part 2 (n = 7–8): Effect of Hypoxic LPC with Other Preconditioning Models. Rats were subjected to the following protocol (fig. 1B): The first group of EPC rats was exposed to sevoflurane with an end-tidal concentration of 1 MAC for 3 × 5 min interspersed with 2 × 5 min exposure and one final 10-min washout period. The second group was exposed to continuous administration of 1 MAC sevoflurane. The third group was exposed to continuous 11 mg·kg⁻¹·h propofol administration. The latter two groups did not receive an anesthesia with α-chloralose.

Part 3 (n = 9): Effect of Combined Hypoxic LPC (LPC16) and EPC. Protocols from parts 1 and 2 of the current study were combined, resulting in the following design (fig. 1C). The first group of rats was exposed to hypoxic LPC combined with sevoflurane early preconditioning. The second group was exposed to hypoxic LPC combined with continuous administration of 1 MAC sevoflurane. The third group was subjected to hypoxic LPC combined with continuous 11 mg·kg⁻¹·h propofol administration.

Western Blot Analysis

For Western blot analysis of myocardial PKCα and PKCe, additional experiments were performed. Six and 28 h after hypoxic exposure (LPC16) was initiated, hearts were excised (n = 12). Hearts from normoxic control animals were excised after exposure to 21% oxygen. Before heart excision, rats underwent a sham operation to follow the same surgical protocol as was used in the infarct size experiments.
After protein determination by the Lowry method, equal amounts of the cytosolic protein fraction were mixed with loading buffer containing Tris-hydrochloric acid, glyceraldehyde-3-phosphate dehydrogenase and bromphenol blue. Samples were vortexed and boiled at 95°C before being subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Samples were loaded on a sodium dodecyl sulfate electrophoresis gel. Proteins were separated by electrophoresis and then transferred to a polyvinylidene membrane by tank blotting. The respective gels were stained with Coomassie Brilliant Blue solution to guarantee equal protein loading. Unspecific binding of the antibody was blocked by incubation with 5% fat dry milk powder solution in Tris-buffered saline for 2 h. Subsequently, the membrane was incubated overnight at 4°C with the respective first antibody at indicated concentrations. After washing in fresh, cold Tris-buffered saline, the blot was subjected to the appropriate Alexa Fluor 688 or Alexa Fluor 788 infrared conjugated secondary antibody for 2 h at room temperature. Immunoreactive bands on the membrane were visualized by a two-channel laser system, and blots were quantified (Odyssey IR Imager®; LI-COR Biosciences, Bad Homburg, Germany).

**Semiquantitative Reverse Transcriptase–Polymerase Chain Reaction Assay**

HO-1 and VEGF messenger ribonucleic acid (mRNA) expression was measured by reverse transcriptase-polymerase chain reaction assay. Total RNA was isolated with Trizol according to the manufacturer’s instructions (Invitrogen, Darmstadt, Germany). Two micrograms total RNA were reverse-transcribed (Promega, Mannheim, Germany). To quantify VEGF, HO-1, and glyceraldelye-3-phosphate dehydrogenase mRNAs, gene-specific primers were used. Details about the primer sequences and reverse transcriptase–polymerase chain reaction conditions are provided in Supplemental Digital Content 1, http://links.lww.com/ALN/A647. Amplified products were resolved by electrophoresis on 2% agarose gels and stained with ethidium bromide. Gels were photographed under ultraviolet transillumination with a digital camera. Images were transferred to a computer for densitometric analysis (Gelscan; BioSciTec, Frankfurt, Germany). Final results were expressed as the ratio of HO-1 and VEGF mRNA to glyceraldehyde-3-phosphate dehydrogenase mRNA for each sample.

**Statistical Analysis**

Normal distribution of the data was tested using the Kolmogorov–Smirnov test. Infarct sizes were analyzed by a one-way analysis of variance and Tukey test. Western blot and reverse transcriptase–polymerase chain reaction data were analyzed by a Kruskal–Wallis and Student–Newman–Keuls test. Data obtained periodically throughout the experiment, such as hemodynamic variables, were analyzed using one-way repeated-measures analysis of variance and Holm–Sidak test. All data are presented as mean ± SD unless otherwise specified. Changes within and between groups were considered statistically significant if P values were less than 0.05 (version 17, SPSS; SPSS Science Software).

**Results**

**Infarct Size Measurement**

As summarized in table 1, hypoxic LPC significantly reduced infarct size at all tested oxygen concentrations (P < 0.001 vs. normoxic control). Cardioprotective effects were similar among the three LPC study groups (P = 0.84, table 1). The

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Mean ± SD Infarct Size, % AAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normoxic control</td>
<td>8</td>
<td>62 ± 6</td>
</tr>
<tr>
<td>LPC16</td>
<td>8</td>
<td>36 ± 11*</td>
</tr>
<tr>
<td>LPC12</td>
<td>8</td>
<td>38 ± 10*</td>
</tr>
<tr>
<td>LPC8</td>
<td>8</td>
<td>39 ± 11*</td>
</tr>
<tr>
<td>LPC16+Calphostin C</td>
<td>7</td>
<td>57 ± 11†</td>
</tr>
<tr>
<td>Calphostin C</td>
<td>8</td>
<td>58 ± 9</td>
</tr>
<tr>
<td>S-PC</td>
<td>7</td>
<td>40 ± 8*</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>7</td>
<td>53 ± 6†</td>
</tr>
<tr>
<td>Propofol</td>
<td>7</td>
<td>56 ± 10</td>
</tr>
<tr>
<td>LPC16+S-PC</td>
<td>9</td>
<td>37 ± 12*</td>
</tr>
<tr>
<td>LPC16+Sevoflurane</td>
<td>9</td>
<td>40 ± 10*</td>
</tr>
<tr>
<td>LPC16+Propofol</td>
<td>9</td>
<td>42 ± 10*</td>
</tr>
</tbody>
</table>

* P < 0.05 vs. normoxic control. † P < 0.05 vs. LPC16. AAR = area at risk; LPC = late preconditioning; LPC16 = LPC, 16% oxygen; LPC12 = LPC, 12% oxygen; LPC8 = LPC, 8% oxygen; Sevoflurane = continuous sevoflurane early preconditioning; S-PC = sevoflurane early preconditioning; Propofol = continuous propofol early preconditioning.

![Fig. 2. Infarct size measurement. Histogram shows the infarct size (area at risk, %) of normoxic control animals, hypoxic LPC with 16% oxygen alone (LPC16), hypoxic LPC16 combined with calphostin C, and calphostin C alone. All data are presented as mean ± SD unless otherwise specified. * P < 0.05 vs. normoxic control. LPC = late preconditioning.](image-url)
PKC inhibitor calphostin C abolished the preconditioning effect of LPC16 ($P < 0.001$) but had no effect on infarct size when it was administered to normoxic control animals ($P = 0.30$, table 1 and fig. 2).

Early preconditioning with intermittent administration of sevoflurane reduced infarct size ($P < 0.01$ vs. normoxic control) to approximately the same magnitude as hypoxic LPC ($P = 0.87$, table 1). In contrast, continuous administration of sevoflurane and propofol was not cardioprotective ($P = 0.77$ and $P = 0.96$, respectively, vs. normoxic control, table 1).

As shown in table 1, the combination of LPC16 with sevoflurane EPC did not provide cardioprotective effects superior to those of each substance alone ($P < 0.05$ vs. normoxic control; $P = 0.87$ vs. LPC16; $P = 0.85$ vs. sevoflurane EPC). The cardioprotective effects of LPC16 were not affected by the two nonprotective interventions with continuous administration of sevoflurane or propofol. In other words, hypoxic LPC was still able to reduce infarct size when it was combined with the continuous administration of sevoflurane or propofol ($P < 0.01$ vs. normoxic control).

**Hemodynamic Variables**

In all groups, heart rate decreased at the end of the experiment compared with baseline values ($P < 0.05$, table 2). Decrease in heart rate failed to reach statistical significance only when rats were exposed to continuous administration of propofol ($P = 0.05$). Decrease in heart rate was paralleled by a decrease in mean aortic pressure ($P < 0.05$). However, continuous administration of sevoflurane, alone or in combination with LPC16, prevented a decrease in mean blood pressure.

**Expression of PKCα and PKCe**

Figure 3 shows that LPC16 was associated with an increased myocardial expression of PKCα at 6 h after the hypoxic stimulus was initiated ($n = 12$; $P = 0.01$ vs. normoxic control). At 28 h, PKCe expression remained elevated and was of approximately the same magnitude as after 6 h ($n = 12$; $P = 0.91$ vs. 6 h; $P = 0.01$ vs. normoxic control). In contrast, at the same time points, myocardial expression of PKCe was not affected by hypoxic LPC16 (PKCα/tubulin ratios: normoxic control, 0.49 ± 0.08; LPC16, 6 h, 0.47 ± 0.05, 28 h, 0.50 ± 0.08; $P = 0.81$; data not shown).

**Expression of HO-1 and VEGF**

Hypoxic preconditioning with 16% oxygen transiently up-regulated the myocardial expression of the hypoxia-inducible factor-1α-dependent genes HO-1 and VEGF (fig. 4 and fig. 5). Six h after hypoxic stimulus was initiated, expression of

---

**Table 2. Mean ± SD Hemodynamic Variables**

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Washout 3</th>
<th>Ischemia 15 min</th>
<th>Reperfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 min</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normoxic control</td>
<td>410 ± 27</td>
<td>403 ± 28</td>
<td>399 ± 19</td>
<td>365 ± 18§</td>
</tr>
<tr>
<td>LPC16</td>
<td>419 ± 34</td>
<td>411 ± 31</td>
<td>407 ± 35</td>
<td>380 ± 30</td>
</tr>
<tr>
<td>LPC12</td>
<td>415 ± 27</td>
<td>408 ± 23</td>
<td>407 ± 20</td>
<td>390 ± 22§</td>
</tr>
<tr>
<td>LPC8</td>
<td>426 ± 33</td>
<td>414 ± 23</td>
<td>407 ± 32</td>
<td>364 ± 35§</td>
</tr>
<tr>
<td>LPC16+Calphostin C</td>
<td>423 ± 16</td>
<td>415 ± 14</td>
<td>428 ± 15</td>
<td>377 ± 15§</td>
</tr>
<tr>
<td>Calphostin C</td>
<td>418 ± 18</td>
<td>411 ± 21</td>
<td>420 ± 21</td>
<td>373 ± 17§</td>
</tr>
<tr>
<td>S-PC</td>
<td>368 ± 37</td>
<td>333 ± 22§$</td>
<td>320 ± 28§+§$</td>
<td>283 ± 17+§$</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>355 ± 25*</td>
<td>359 ± 33</td>
<td>339 ± 33</td>
<td>341 ± 39</td>
</tr>
<tr>
<td>Propofol</td>
<td>399 ± 35</td>
<td>380 ± 54</td>
<td>408 ± 24</td>
<td>376 ± 24</td>
</tr>
<tr>
<td>LPC16+S-PC</td>
<td>414 ± 32</td>
<td>368 ± 24§</td>
<td>377 ± 24§</td>
<td>343 ± 15§</td>
</tr>
<tr>
<td>LPC16+Sevoflurane</td>
<td>359 ± 24†</td>
<td>348 ± 27†</td>
<td>351 ± 36†</td>
<td>349 ± 15</td>
</tr>
<tr>
<td>LPC16+Propofol</td>
<td>428 ± 24</td>
<td>418 ± 35</td>
<td>392 ± 57</td>
<td>398 ± 51</td>
</tr>
<tr>
<td>Mean aortic pressure, mmHg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normoxic control</td>
<td>140 ± 16</td>
<td>135 ± 25</td>
<td>111 ± 32</td>
<td>89 ± 26§</td>
</tr>
<tr>
<td>LPC16</td>
<td>130 ± 19</td>
<td>127 ± 20</td>
<td>114 ± 20</td>
<td>95 ± 23§</td>
</tr>
<tr>
<td>LPC12</td>
<td>140 ± 9</td>
<td>128 ± 11</td>
<td>117 ± 17§</td>
<td>103 ± 19§</td>
</tr>
<tr>
<td>LPC8</td>
<td>124 ± 19</td>
<td>121 ± 23</td>
<td>108 ± 27</td>
<td>88 ± 21§</td>
</tr>
<tr>
<td>LPC16+Calphostin C</td>
<td>138 ± 18</td>
<td>130 ± 13</td>
<td>113 ± 24§</td>
<td>100 ± 18§</td>
</tr>
<tr>
<td>Calphostin C</td>
<td>143 ± 5</td>
<td>132 ± 5§</td>
<td>128 ± 7§</td>
<td>88 ± 14§</td>
</tr>
<tr>
<td>S-PC</td>
<td>119 ± 18</td>
<td>86 ± 17§</td>
<td>70 ± 12§</td>
<td>65 ± 7§</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>100 ± 21*</td>
<td>116 ± 25</td>
<td>113 ± 25</td>
<td>105 ± 15</td>
</tr>
<tr>
<td>Propofol</td>
<td>144 ± 13</td>
<td>134 ± 20</td>
<td>136 ± 10</td>
<td>116 ± 17§</td>
</tr>
<tr>
<td>LPC16+S-PC</td>
<td>126 ± 10</td>
<td>107 ± 10§</td>
<td>99 ± 15§</td>
<td>74 ± 7§</td>
</tr>
<tr>
<td>LPC16+Sevoflurane</td>
<td>108 ± 19</td>
<td>126 ± 13§</td>
<td>125 ± 12§</td>
<td>113 ± 11</td>
</tr>
<tr>
<td>LPC16+Propofol</td>
<td>131 ± 25</td>
<td>121 ± 27</td>
<td>100 ± 41§</td>
<td>101 ± 23§</td>
</tr>
</tbody>
</table>

* $P < 0.05$ vs. normoxic control. † $P < 0.05$ vs. LPC16. ‡ $P < 0.05$ vs. LPC16+S-PC. § $P < 0.05$ vs. baseline.  
  
LPC = late preconditioning; LPC16 = LPC, 16% oxygen; LPC12 = LPC, 12% oxygen; LPC8 = LPC, 8% oxygen; Sevoflurane = continuous sevoflurane early preconditioning; S-PC = sevoflurane early preconditioning; Propofol = continuous propofol early preconditioning.
HO-1 and VEGF increased by approximately 60% and 28%, respectively (each \( p < 0.05 \)). However, at 28 h, expression of HO-1 (\( p = 0.50 \)) and VEGF (\( p = 0.75 \)) had returned to baseline values.

**Discussion**

Ischemic preconditioning represents a powerful and reproducible tool of cardioprotection against myocardial ischemia, yet this knowledge has not been translated into routine clinical use. Clinical applicability of this principle is limited by the nature of the fact that invasive procedures are required to induce ischemia. Although application might be possible in some situations (e.g., intermittent aortic cross-clamping during coronary artery bypass surgery), it simply is not in many others (e.g., nonthoracic surgery). Much effort has, therefore, been focused on identifying clinically relevant preconditioning stimuli that are noninvasive and easy to administer.

Among various other stimuli (e.g., nitric oxide, volatile anesthetics), hypoxia may represent a potent preconditioning tool. Hypoxia resembles the stress that can ultimately lead to myocardial infarction (i.e., cellular hypoxia/anoxia). One advantage of hypoxic rather than ischemic preconditioning is that systemic administration affects multiple organ systems, potentially offering protection against ischemic insults to the brain, liver, kidney, and other organ systems.

As indicated by several *in vitro* studies, intermittent exposure to 10% oxygen for 4 h induced late cardioprotection in the isolated rat heart. Moreover, continuous hypoxic exposure to 10% oxygen for 4 h followed by 24 h of reoxygenation reduced infarct size in the isolated mouse heart, whereas shorter exposure times (30 min and 2 h, respectively) were ineffective. In contrast, another study found that 10% oxygen for 4 h had no cardioprotective effects. Although different protocols of hypoxia-induced myocardial preconditioning have proven effective *in vitro*, protective effects remain to be established *in vivo*.

**Hypoxia Induces LPC In Vivo**

In the current study, we demonstrate that continuous exposure to 4-h hypoxia followed by 24 h of normoxic reoxygenation induces LPC in the rat heart *in vivo*, reducing infarct size by nearly 40% when compared with nonpreconditioned myocardium. It is noteworthy that the extent of cardioprotection induced by 16% oxygen was comparable with that offered by 12% and 8% oxygen. However, because infarct size increased slightly with a decrease in oxygen concentration (i.e., area at risk, %: LPC16, 36; LPC12, 38; LPC8, 39), our results do not exclude the possibility of less pronounced cardioprotective effects with decreased oxygen concentrations. Indeed, Béguin et al. showed that intermittent hypoxia with 10% oxygen for 4 h significantly reduced infarct size in a rat model whereas the same protocol with 5% oxygen significantly increased infarct size. This observation suggests that severe hypoxia renders the myocardium more sen-
The experiments, EPC with sevoflurane reduced infarct size by published effects of EPC with sevoflurane. In these original protective effects of hypoxic LPC compared with the well-established effects of EPC with sevoflurane, highlighting the applicability and potential relevance of hypoxic LPC in the clinical setting.

Potency of Hypoxia-induced LPC

We next investigated the potency of the observed cardioprotective effects of hypoxic LPC compared with the well-established effects of EPC with sevoflurane. In these original experiments, EPC with sevoflurane reduced infarct size by approximately 38%, in line with previous findings. The cardioprotective effects of sevoflurane EPC and hypoxic LPC are comparable. In contrast, when sevoflurane was administered continuously, without a washout period before myocardial ischemia was induced, no reduction in infarct size was observed. This finding is in accord those of Bein et al., who showed that continuous administration of 1 MAC sevoflurane from induction to start of cardiopulmonary bypass did not result in cardioprotective effects when compared with the normoxic control group. However, when presurgical sevoflurane administration was interrupted for 10 min, improved myocardial performance and decreased postoperative troponin T values were observed. These data, in conjunction with our findings, suggest that interrupted administration of anesthetics may be an essential feature for the occurrence of clinically relevant cardioprotective effects. This hypothesis is supported by our observation that continuous administration of propofol also exerted no cardioprotective effects.

These findings are of special interest for clinical scenarios where myocardial ischemia occurs by chance and cannot be timed, as is possible, for example, in coronary artery bypass surgery. In the situation where a washout phase cannot be planned, myocardial ischemia likely occurs during the administration of anesthetics (i.e., when sevoflurane and propofol were not cardioprotective in our study). In such situations, clinical applicability of EPC is clearly limited. Thus, as noted elsewhere, LPC is likely of greater clinical relevance than EPC because it lasts 30–40 times longer and can easily be initiated before an expected ischemic event occurs. Because our results show that LPC with hypoxia was as cardioprotective as EPC with sevoflurane, this finding underlines the potential relevance of hypoxia as LPC stimulus. This result may be especially relevant in conjunction with previous data indicating that LPC, but not EPC, protects against reversible postischemic contractile dysfunction (i.e., myocardial “stunning”).

Hypoxic LPC Cannot be Enhanced by Modified Anesthetic Techniques

A study by Müllenheim et al. showed that combining ischemic LPC with ischemic EPC led to enhanced cardioprotection compared with each stimulus alone. The same group showed that cardioprotection by ischemic LPC could be increased by sevoflurane-induced EPC. Therefore, we investigated whether the cardioprotective effects of hypoxic LPC could be enhanced by EPC with sevoflurane or by continuous administration of sevoflurane or propofol. It is noteworthy that, to the best of our knowledge, there is no study investigating the cardioprotective effects of LPC combined with continuous administration of sevoflurane or propofol. Our results demonstrate that none of the tested combinations was superior to the cardioprotection elicited by hypoxic LPC alone. However, our results also demonstrated that hypoxic LPC was not impaired by continuous administration of sevoflurane or propofol, highlighting the applicability and potential relevance of hypoxic LPC in the clinical setting.

Signaling Cascade of Hypoxic LPC

Myocardial hypoxia triggers a wide range of profound cellular responses, including regulation of gene expression. In several studies, PKC, a ubiquitous intracellular mediator, has been shown to play a pivotal role in the signaling pathway of LPC, as elicited by a variety of agents. Notably, the isoform PKC\(\varepsilon\) seems to be responsible for the development of delayed cardioprotection, although, in some studies, PKC\(\alpha\) has also been implicated in provoking ischemic preconditioning of the heart.
Our results show that the PKC inhibitor calphostin C completely blocked the cardioprotective effects of hypoxic LPC, supporting the close association between PKC activation and the infarct size limitation conferred by hypoxic LPC. Although calphostin C is not isoform-selective, it has been shown to inhibit the novel isoforms of PKC, including PKCε, more efficiently than conventional ones.\(^{35}\) Moreover, a previous study\(^{36}\) characterizing the expression of PKC isoforms in rat ventricular myocytes found that the dominant isoform was PKCε. Indeed, we found that 6 h after the preconditioning stimulus was initiated, the expression of PKCε was increased, and this increase remained stable until myocardial ischemia was induced (i.e., after 28 h). In contrast, the expression of PKCa was not affected by hypoxic LPC. These observations indicate that PKCε, but not PKCa, is the dominant isoform involved in the cardioprotective effects of hypoxic LPC in the rat heart in vivo. This finding is in line with a series of previous studies\(^{34,37,38}\) showing that translocation and activation of PKCε—but not of the PKC isoforms α, β, γ, δ, ζ, η, ι, λ, and μ—are necessary for ischemic LPC in vivo. The reasons for the conflict between study findings regarding the involvement of PKCa in mediating LPC are unclear but may be related to species differences (canine, rabbit, humans, and rat) and type of preconditioning (ischemic vs. hypoxic). However, we cannot exclude the possibility that PKC isoforms not studied in the current investigation may contribute to the cardioprotection elicited by hypoxic LPC in the rat.

Previous studies suggest that PKCε plays a pivotal role in the up-regulation of the hypoxia-inducible factor-1α-dependent genes HO-1 and VEGF,\(^{39,40}\) both of which have previously been implicated in mediating hypoxic LPC.\(^{16–18,41}\) HO-1 degrades heme and generates carbon monoxide and bilirubin, which may have antioxidant and/or antiinflammatory effects.\(^{42}\) Indeed, mice overexpressing cardiac-specific HO-1 show a significant reduction in infarct size after ischemia-reperfusion.\(^{18}\) VEGF regulates local oxygen supply and may be important in ischemia reperfusion because it mediates neovascularization during myocardial ischemia.\(^{43,44}\) Our finding of the transient up-regulation of HO-1 and VEGF mRNA provides further evidence for the involvement of these two effector genes in hypoxic LPC. Along with the hypothesis that PKCε is involved in HO-1 and VEGF expression, it seems conceivable that inhibition of PKC prevents the HO-1- and VEGF-mediated reduction in infarct size. Indeed, the observation that calphostin C abolished the cardioprotective effects of hypoxic LPC is consistent with this hypothesis. Moreover, our results related to calphostin C support the assumption that PKCε lies upstream in the signaling pathway of HO-1 and VEGF expression in the rat myocardium, as proposed by others.\(^{16}\)

**Limitations of the Study**

One limitation of the current study is that we did not determine the oxygen threshold below which hypoxia starts to exert cardioprotective effects. We cannot exclude the possibility that oxygen concentrations higher than 16%, but lower than 21%, are also cardioprotective.

Another limitation of our study is that pharmacologic inhibitors such as calphostin C may affect other enzymes to a certain extent. Their specificity strongly depends on the concentration used. For example, calphostin C inhibits PKC with a half-maximal inhibitory concentration of 50 nM. Other kinases, such as protein kinase A (half-maximal inhibitory concentration more than 50 μM), p60src (half-maximal inhibitory concentration more than 50 μM), and protein kinase G (half-maximal inhibitory concentration more than 25 μM) are inhibited only at higher concentrations.

**Conclusion**

In summary, our results show that (1) hypoxic LPC results in profound protection against myocardial ischemia–reperfusion injury in the rat heart in vivo, as evidenced by a significant decrease in infarct size; (2) mild hypoxia (16% oxygen) induces cardioprotection of approximately the same magnitude as moderate (12% oxygen) and severe (8% oxygen) hypoxia; (3) the cardioprotective effects of hypoxia-induced LPC are as powerful as those of EPC with sevoflurane; and (4) PKCε is the dominant isoform involved in the cardioprotective effects of hypoxic LPC in the rat heart in vivo. These findings may provide a conceptual framework for developing novel therapeutic strategies aimed at powerful cardioprotection, especially in situations where myocardial ischemia occurs by chance and early preconditioning strategies are not applicable.

The authors thank Yvonne Gruber, M.T.A. (Technician, Department of Anesthesiology, University Hospital of Düsseldorf, Düsseldorf, Germany), and Elmar Menold, M.T.A. (Technician, Department of Internal Medicine VII, Division of Sports Medicine, University of Heidelberg, Heidelberg, Germany), for excellent technical support.

**References**

17. Thirunavukkarasu M, Juhasz B, Zhan L, Menon VP, Tosaki et al.
39. Kawata H, Yoshida K, Kawamoto A, Kurioka H, Takase E,


